ANO2

Anoctamin-2 · Q9NQ90 · ANO2 on Sugi Atlas →

1,943 patent compounds predicted against ANO2, 1,498 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4147839 SCHEMBL4147839 0.79 5/20
SCHEMBL4135518 SCHEMBL4135518 0.76 5/20
SCHEMBL4150336 SCHEMBL4150336 0.68 4/20
SCHEMBL6435397 SCHEMBL6435397 0.47 4/20
SCHEMBL4139983 SCHEMBL4139983 0.77 3/20
SCHEMBL4145647 SCHEMBL4145647 0.77 3/20
SCHEMBL4148960 SCHEMBL4148960 0.75 3/20
SCHEMBL4139676 SCHEMBL4139676 0.73 3/20
SCHEMBL4140424 SCHEMBL4140424 0.71 3/20
SCHEMBL4134815 SCHEMBL4134815 0.69 3/20
SCHEMBL4134799 SCHEMBL4134799 0.81 2/20
SCHEMBL4151223 SCHEMBL4151223 0.81 2/20
SCHEMBL4136619 SCHEMBL4136619 0.80 2/20
SCHEMBL4147246 SCHEMBL4147246 0.79 2/20
SCHEMBL4140756 SCHEMBL4140756 0.77 2/20
SCHEMBL4145029 SCHEMBL4145029 0.77 2/20
SCHEMBL4153255 SCHEMBL4153255 0.77 2/20
SCHEMBL4141379 SCHEMBL4141379 0.75 2/20
SCHEMBL4132190 SCHEMBL4132190 0.70 2/20
SCHEMBL4140828 SCHEMBL4140828 0.70 2/20

Clinical trials — most relevant to ANO2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. PHASE2NOT_YET_RECRUITING
The Response To Ajmaline Provocation in Healthy Subjects PHASE2UNKNOWN
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy PHASE2RECRUITING
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction PHASE2ACTIVE_NOT_RECRUITING
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants nanRECRUITING
3 Year Follow up on ANO5 Patients nanACTIVE_NOT_RECRUITING
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Piezo2-related Arthrogryposis & physiopathOLOgy 3 nanNOT_YET_RECRUITING
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Multidisciplinary Study of Right Ventricular Dysplasia nanCOMPLETED
The Genetic Basis of Atrial Fibrillation (AF) nanCOMPLETED
The Role of Biomarkers in Inherited Cardiac Conditions nanWITHDRAWN
Feasibility of Improving Risk Stratification in Brugada Syndrome nanCOMPLETED
Families' Experiences of Paediatric ICC Diagnosis nanUNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Determinants of Cardiorespiratory Fitness and Effects of HIIT in Patients With ANOCA Obstructive Coronary Artery Disease(ANOCA) nanRECRUITING
Painful Channelopathies Study nanUNKNOWN
Heart and Skeletal Muscle Problems in Neuroacanthocytosis nanCOMPLETED
Effect of Hypertonic Sodium Chloride on Urinary Biomarkers in Healthy Subjects and Patients With Chronic Kidney Disease nanCOMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
Impaired Secretory IgA and Mucosal Immunity in Cystic Fibrosis nanUNKNOWN
Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders nanRECRUITING
Early PKD Observational Cohort Study nanRECRUITING
Microneurographic Assessment of Peripheral Nerves in Healthy Volunteers and Individuals With Sensory Dysfunction Caused by Inherited Mutations in the PIEZO2 Gene nanRECRUITING
The Natural History of TRPV4 Neuropathy nanRECRUITING
New Biomarkers and Difficult-to-treat Hypertension nanCOMPLETED
Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis nanRECRUITING
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a ANO2 binder may also engage these)

ProteinNameSimilarity
Q8CFW1 0.998 Q8CFW1 →
Q7TQ69 0.997 Q7TQ69 →
Q8BHY3 0.997 Q8BHY3 →
Q14AT5 0.995 Q14AT5 →
Q11069 0.994 Q11069 →
Q0JJZ6 0.993 Q0JJZ6 →
ANO1 Anoctamin-1 0.992 landscape →
Q5YCC7 0.992 Q5YCC7 →
Q75UR0 0.992 Q75UR0 →
Q75V66 0.992 Q75V66 →
TRPC1 Short transient receptor potential channel 1 0.991 landscape →
Q9QX29 0.991 Q9QX29 →
Q9FKY5 0.991 Q9FKY5 →
Q6IWH7 0.990 Q6IWH7 →
P93766 0.990 P93766 →
Q6P9J9 0.990 Q6P9J9 →
P19334 0.989 P19334 →
Q7T047 0.989 Q7T047 →
O35119 0.989 O35119 →
Q61056 0.989 Q61056 →
Q7Z5M5 0.988 Q7Z5M5 →
D3KZG3 0.988 D3KZG3 →
Q6IFT6 0.988 Q6IFT6 →
TRPC4 Short transient receptor potential channel 4 0.988 landscape →
P48994 0.988 P48994 →
Q02739 0.988 Q02739 →
P18860 0.988 P18860 →
Q4KMQ2 0.988 Q4KMQ2 →
P51914 0.988 P51914 →
Q21123 0.988 Q21123 →